This 2004 review by Jan L. Shifren explores the multifactorial causes of female sexual dysfunction (FSD), emphasizing the emerging recognition of androgen deficiency as a contributing factor. While psychological, relational, and physiological issues are primary considerations, low androgen levels—due to aging, oophorectomy, adrenal insufficiency, or hypopituitarism—may lead to decreased libido
This randomized controlled trial examined the effects of combining testosterone and vardenafil (a PDE5 inhibitor) on cognitive, affective, and physiological sexual functions in 28 women with sexual dysfunction. The study found that in women with low initial attention to sexual cues, testosterone increased sensitivity to these cues, and the combination
Bremelanotide, a melanocortin receptor agonist, has been FDA-approved as an as-needed treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials demonstrated statistically significant improvements in sexual desire and reductions in distress related to low libido, though the overall clinical benefit was considered modest. Administered via subcutaneous injection
Bremelanotide, a melanocortin receptor agonist, has shown statistically significant improvements in sexual desire and reduced distress related to hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered as a subcutaneous injection on an as-needed basis, it provides an on-demand treatment option. However, the overall clinical benefit is modest, and nausea
This article explores the use of androgen therapy in addressing female sexual dysfunction, highlighting the role of androgens in female sexual health, libido, and overall well-being. It evaluates clinical evidence supporting androgen therapy, including its potential benefits in improving sexual desire and function, while also addressing associated risks. The study
This randomized controlled trial investigated the effectiveness of combining testosterone with a phosphodiesterase type 5 (PDE5) inhibitor to improve sexual satisfaction in women diagnosed with hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD) who exhibit low sensitivity to sexual cues. The study included 36 premenopausal women aged
This narrative review explores the neurobiological mechanisms underlying hypoactive sexual desire disorder (HSDD) in women, focusing on the inhibitory role of serotonin in sexual desire. The review highlights that serotonin overactivity may contribute to HSDD by suppressing excitatory pathways involved in sexual function. It discusses pharmacologic treatments targeting serotonin, particularly
This study validated the Female Sexual Distress Scale-Revised (FSDS-R) as a reliable tool for assessing sexual distress in women with hypoactive sexual desire disorder (HSDD). Conducted across 27 North American centers, it included 296 women aged 18-50 categorized into those with HSDD, other female sexual dysfunctions (FSD), or no FSD.
In the study “Women with low libido: correlation of decreased androgen levels with female sexual function index” (Int J Impot Res, 2005, PMID: 15592425), researchers investigated the relationship between androgen levels and sexual function in women with low libido compared to age-matched controls. The study included 20 premenopausal and 20
This observational study examined sexual dysfunction (SD) in peri- and postmenopausal women, assessing its incidence, pharmacological treatment options, and associated risks. Findings indicate that SD increases with age and worsens during menopause, with systemic hormone therapies (estrogen, estrogen/progesterone, estrogen/testosterone, and tibolone) improving symptoms. Local estrogen treatments effectively relieve vaginal dryness
